Portfolio Holdings Detail for ISIN IE00B52SFT06
| Stock Name / Fund | iShares MSCI USA UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares VII Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300Q7FFITMZ2PFZ28 |
| ETF Ticker | CU1(GBX) LSE |
| ETF Ticker | SXR4(EUR) F |
| ETF Ticker | CSUS.LS(USD) CXE |
| ETF Ticker | CSUS.MI(EUR) CXE |
| ETF Ticker | CSUSz(USD) CXE |
| ETF Ticker | SXR4.DE(EUR) CXE |
| ETF Ticker | CSUS(EUR) Euronext Amsterdam |
| ETF Ticker | CU1.L(GBP) LSE |
Holdings detail for ALNY
| Stock Name | Alnylam Pharmaceuticals Inc |
| Ticker | ALNY(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US02043Q1076 |
| LEI | 529900S3ZI14OWRJII50 |
Show aggregate ALNY holdings
News associated with ALNY
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
- The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
- Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
- Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028
- (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
- Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028
- (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
- ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
- Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
- Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
- Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
- LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
- XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
- Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer
- Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
- Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
- Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
- Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
- Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial
- Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
- Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
- Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.
- Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
- Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
- Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
- Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
- Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade
- Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
- Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52
iShares MSCI USA UCITS ETF USD (Acc) ALNY holdings
| Date | Number of ALNY Shares Held | Base Market Value of ALNY Shares | Local Market Value of ALNY Shares | Change in ALNY Shares Held | Change in ALNY Base Value | Current Price per ALNY Share Held | Previous Price per ALNY Share Held |
|---|
| 2025-12-03 (Wednesday) | 6,743 | USD 3,191,394 | USD 3,191,394 | 0 | USD 56,371 | USD 473.29 | USD 464.93 |
| 2025-12-02 (Tuesday) | 6,743 | USD 3,135,023 | USD 3,135,023 | -21 | USD 60,379 | USD 464.93 | USD 454.56 |
| 2025-12-01 (Monday) | 6,764 | USD 3,074,644 | USD 3,074,644 | 0 | USD 22,524 | USD 454.56 | USD 451.23 |
| 2025-11-28 (Friday) | 6,764 | USD 3,052,120 | USD 3,052,120 | 0 | USD 41,328 | USD 451.23 | USD 445.12 |
| 2025-11-27 (Thursday) | 6,764 | USD 3,010,792 | USD 3,010,792 | 0 | USD 0 | USD 445.12 | USD 445.12 |
| 2025-11-26 (Wednesday) | 6,764 | USD 3,010,792 | USD 3,010,792 | 0 | USD 103,625 | USD 445.12 | USD 429.8 |
| 2025-11-25 (Tuesday) | 6,764 | USD 2,907,167 | USD 2,907,167 | 0 | USD -29,965 | USD 429.8 | USD 434.23 |
| 2025-11-24 (Monday) | 6,764 | USD 2,937,132 | USD 2,937,132 | 210 | USD 77,097 | USD 434.23 | USD 436.38 |
| 2025-11-21 (Friday) | 6,554 | USD 2,860,035 | USD 2,860,035 | 84 | USD -24,226 | USD 436.38 | USD 445.79 |
| 2025-11-20 (Thursday) | 6,470 | USD 2,884,261 | USD 2,884,261 | 0 | USD -96,856 | USD 445.79 | USD 460.76 |
| 2025-11-19 (Wednesday) | 6,470 | USD 2,981,117 | USD 2,981,117 | 21 | USD -256 | USD 460.76 | USD 462.3 |
| 2025-11-18 (Tuesday) | 6,449 | USD 2,981,373 | USD 2,981,373 | 693 | USD 330,505 | USD 462.3 | USD 460.54 |
| 2025-11-17 (Monday) | 5,756 | USD 2,650,868 | USD 2,650,868 | 0 | USD 65,503 | USD 460.54 | USD 449.16 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ALNY by Blackrock for IE00B52SFT06
Show aggregate share trades of ALNY| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-12-02 | SELL | -21 | 472.480 | 453.330 | 455.245 | USD -9,560 | 317.01 Loss of -2,903 on sale |
| 2025-11-24 | BUY | 210 | 444.670 | 420.345 | 422.778 | USD 88,783 | 313.34 |
| 2025-11-21 | BUY | 84 | 449.530 | 433.500 | 435.103 | USD 36,549 | 312.75 |
| 2025-11-19 | BUY | 21 | 465.320 | 456.900 | 457.742 | USD 9,613 | 311.37 |
| 2025-11-18 | BUY | 693 | 469.110 | 456.270 | 457.554 | USD 317,085 | 310.62 |
| 2025-11-03 | BUY | 21 | 457.260 | 429.615 | 432.379 | USD 9,080 | 302.98 |
| 2025-10-29 | BUY | 42 | 481.590 | 482.730 | 482.616 | USD 20,270 | 300.45 |
| 2025-10-24 | BUY | 21 | 463.430 | 469.290 | 468.704 | USD 9,843 | 298.62 |
| 2025-10-17 | BUY | 21 | 481.670 | 492.620 | 491.525 | USD 10,322 | 294.71 |
| 2025-10-03 | BUY | 42 | 456.350 | 465.010 | 464.144 | USD 19,494 | 290.81 |
| 2025-10-01 | BUY | 21 | 460.650 | 467.420 | 466.743 | USD 9,802 | 289.85 |
| 2025-09-30 | BUY | 42 | 456.000 | 459.300 | 458.970 | USD 19,277 | 288.91 |
| 2025-09-29 | BUY | 21 | 447.490 | 451.630 | 451.216 | USD 9,476 | 288.01 |
| 2025-09-24 | BUY | 231 | 458.370 | 462.690 | 462.258 | USD 106,782 | 285.18 |
| 2025-09-15 | BUY | 21 | 461.140 | 466.240 | 465.730 | USD 9,780 | 281.12 |
| 2025-09-12 | SELL | -21 | 465.890 | 475.690 | 474.710 | USD -9,969 | 280.02 Loss of -4,088 on sale |
| 2025-09-05 | BUY | 21 | 452.000 | 455.280 | 454.952 | USD 9,554 | 274.34 |
| 2025-07-17 | SELL | -21 | 324.690 | 329.870 | 329.352 | USD -6,916 | 271.63 Loss of -1,212 on sale |
| 2025-07-15 | SELL | -21 | 311.120 | 316.900 | 316.322 | USD -6,643 | 271.05 Loss of -951 on sale |
| 2025-07-10 | BUY | 42 | 322.640 | 324.820 | 324.602 | USD 13,633 | 270.12 |
| 2025-07-02 | BUY | 42 | 329.770 | 330.000 | 329.977 | USD 13,859 | 267.83 |
| 2025-06-27 | BUY | 63 | 322.830 | 323.200 | 323.163 | USD 20,359 | 267.04 |
| 2025-05-28 | SELL | -21 | 285.560 | 291.540 | 290.942 | USD -6,110 | 260.26 Loss of -644 on sale |
| 2025-04-14 | BUY | 38 | 240.010 | 241.830 | 241.648 | USD 9,183 | 259.43 |
| 2025-04-11 | BUY | 38 | 237.770 | 240.000 | 239.777 | USD 9,112 | 259.67 |
| 2025-04-04 | SELL | -836 | 235.740 | 259.160 | 256.818 | USD -214,700 | 261.27 Profit of 3,721 on sale |
| 2025-03-19 | SELL | -38 | 253.440 | 255.350 | 255.159 | USD -9,696 | 260.06 Profit of 186 on sale |
| 2025-03-17 | SELL | -38 | 253.110 | 253.300 | 253.281 | USD -9,625 | 260.38 Profit of 270 on sale |
| 2025-03-12 | BUY | 76 | 242.430 | 246.370 | 245.976 | USD 18,694 | 261.18 |
| 2025-03-11 | BUY | 76 | 238.740 | 243.450 | 242.979 | USD 18,466 | 261.51 |
| 2025-03-10 | BUY | 228 | 233.070 | 244.330 | 243.204 | USD 55,451 | 261.93 |
| 2025-03-07 | BUY | 76 | 244.520 | 251.120 | 250.460 | USD 19,035 | 262.20 |
| 2025-03-06 | BUY | 38 | 248.130 | 252.840 | 252.369 | USD 9,590 | 262.41 |
| 2025-03-05 | BUY | 38 | 249.230 | 249.820 | 249.761 | USD 9,491 | 262.62 |
| 2025-03-04 | BUY | 114 | 242.930 | 244.670 | 244.496 | USD 27,873 | 262.93 |
| 2025-03-03 | BUY | 76 | 243.530 | 250.000 | 249.353 | USD 18,951 | 263.24 |
| 2025-02-27 | BUY | 190 | 237.100 | 246.380 | 245.452 | USD 46,636 | 263.95 |
| 2025-02-26 | BUY | 76 | 243.860 | 251.600 | 250.826 | USD 19,063 | 264.29 |
| 2025-02-18 | BUY | 114 | 250.000 | 260.000 | 259.000 | USD 29,526 | 265.98 |
| 2025-02-05 | BUY | 38 | 276.310 | 278.440 | 278.227 | USD 10,573 | 265.44 |
| 2025-01-31 | BUY | 38 | 271.310 | 279.340 | 278.537 | USD 10,584 | 264.94 |
| 2024-12-30 | BUY | 76 | 236.010 | 236.950 | 236.856 | USD 18,001 | 264.60 |
| 2024-11-20 | BUY | 152 | 248.790 | 249.100 | 249.069 | USD 37,858 | 274.94 |
| 2024-11-18 | BUY | 190 | 232.270 | 242.490 | 241.468 | USD 45,879 | 280.15 |
| 2024-11-12 | BUY | 38 | 268.950 | 270.770 | 270.588 | USD 10,282 | 280.89 |
| 2024-11-07 | BUY | 190 | 272.220 | 275.070 | 274.785 | USD 52,209 | 281.83 |
| 2024-10-24 | BUY | 38 | 293.690 | 301.050 | 300.314 | USD 11,412 | 294.45 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ALNY
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 216,727 | 3,259 | 396,243 | 54.7% |
| 2025-09-18 | 172,875 | 397 | 386,432 | 44.7% |
| 2025-09-17 | 246,547 | 167 | 472,292 | 52.2% |
| 2025-09-16 | 88,846 | 60 | 226,336 | 39.3% |
| 2025-09-15 | 148,258 | 13,572 | 435,689 | 34.0% |
| 2025-09-12 | 134,122 | 300 | 244,968 | 54.8% |
| 2025-09-11 | 219,868 | 7,820 | 411,702 | 53.4% |
| 2025-09-10 | 543,326 | 7,595 | 916,898 | 59.3% |
| 2025-09-09 | 705,540 | 33,731 | 1,550,899 | 45.5% |
| 2025-09-08 | 175,158 | 440 | 388,715 | 45.1% |
| 2025-09-05 | 127,116 | 335 | 311,252 | 40.8% |
| 2025-09-04 | 110,930 | 2,555 | 236,568 | 46.9% |
| 2025-09-03 | 182,386 | 8,982 | 562,921 | 32.4% |
| 2025-09-02 | 132,770 | 14,416 | 358,476 | 37.0% |
| 2025-08-29 | 93,216 | 2,181 | 276,594 | 33.7% |
| 2025-08-28 | 60,182 | 1,254 | 226,865 | 26.5% |
| 2025-08-27 | 277,667 | 1,084 | 440,577 | 63.0% |
| 2025-08-26 | 243,404 | 919 | 447,421 | 54.4% |
| 2025-08-25 | 156,551 | 15,662 | 374,276 | 41.8% |
| 2025-08-22 | 228,596 | 1,309 | 408,152 | 56.0% |
| 2025-08-21 | 123,996 | 2,862 | 248,300 | 49.9% |
| 2025-08-20 | 149,638 | 13,723 | 316,983 | 47.2% |
| 2025-08-19 | 144,320 | 1,143 | 308,399 | 46.8% |
| 2025-08-18 | 371,318 | 34,264 | 525,786 | 70.6% |
| 2025-08-15 | 104,018 | 13,245 | 265,620 | 39.2% |
| 2025-08-14 | 133,272 | 4,443 | 505,528 | 26.4% |
| 2025-08-13 | 183,271 | 1,390 | 1,017,623 | 18.0% |
| 2025-08-12 | 173,045 | 4,046 | 693,018 | 25.0% |
| 2025-08-11 | 239,199 | 7,600 | 451,248 | 53.0% |
| 2025-08-08 | 168,755 | 3,199 | 466,744 | 36.2% |
| 2025-08-07 | 308,810 | 4,452 | 527,399 | 58.6% |
| 2025-08-06 | 202,151 | 12,590 | 548,349 | 36.9% |
| 2025-08-05 | 256,295 | 13,237 | 826,283 | 31.0% |
| 2025-08-04 | 411,114 | 36,303 | 729,949 | 56.3% |
| 2025-08-01 | 350,060 | 60,108 | 764,943 | 45.8% |
| 2025-07-31 | 829,191 | 6,023 | 1,541,015 | 53.8% |
| 2025-07-30 | 533,885 | 14,703 | 942,788 | 56.6% |
| 2025-07-29 | 164,268 | 55 | 384,537 | 42.7% |
| 2025-07-28 | 150,240 | 69 | 571,965 | 26.3% |
| 2025-07-25 | 90,782 | 429 | 298,801 | 30.4% |
| 2025-07-24 | 132,001 | 11,546 | 286,155 | 46.1% |
| 2025-07-23 | 184,149 | 63 | 312,340 | 59.0% |
| 2025-07-22 | 134,761 | 7,553 | 524,612 | 25.7% |
| 2025-07-21 | 113,303 | 101 | 243,119 | 46.6% |
| 2025-07-18 | 84,117 | 9 | 196,317 | 42.8% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy